NCT07541287Phase 2Recruiting

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Study sponsor: Jade Biosciences, Inc. · JBIO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-01Estimated
Enrollment · participants30Estimated
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety and tolerability of JADE101 in participants with IgA nephropathy. After: Measure: Incidence of treatment-emergent adverse events (safety and tolerability).

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source